论文部分内容阅读
目的:观察蚓激酶对肾病综合征患者血脂及血液流变学的影响。方法:62例原发性肾病综合征患者随机分2组。在基础治疗同时,治疗组予蚓激酶胶囊60万U,po,tid,治疗6周。对照组先给予低分子肝素注射剂4 100 u·d~(-1)皮下注射2周,再予双嘧达莫片100 mg,po,tid,治疗4周,同时辛伐他汀片40 mg,po,qd,治疗6周。观察两组治疗前后血液流变学和血脂变化。结果:两组治疗前后血液流变学与血脂等各项指标比较,差异均无统计学意义(P>0.05);两组治疗后血液流变学及血脂各指标与治疗前比较,差异有统计学意义(P<0.05)。结论:蚓激酶能改善肾病综合征患者血流动力学异常与脂质代谢紊乱。
Objective: To observe the effect of lumbrokinase on plasma lipids and hemorheology in patients with nephrotic syndrome. Methods: 62 patients with primary nephrotic syndrome were randomly divided into two groups. At the same time as the basic treatment, the treatment group received Luperoxidase 600,000 U, po, tid for 6 weeks. The control group was given subcutaneous injection of low molecular weight heparin 4 100 u · d -1 for 2 weeks and then treated with dipyridamole 100 mg, po, tid for 4 weeks. Simvastatin 40 mg, po , qd, for 6 weeks. The changes of blood rheology and blood lipid in two groups before and after treatment were observed. Results: Before and after treatment, the indexes of hemorrheology and blood lipids were not significantly different between the two groups (P> 0.05). The indexes of hemorrheology and blood lipids after treatment in both groups were statistically different from those before treatment Significance (P <0.05). Conclusion: Lumbrokinase can improve hemodynamic abnormalities and lipid metabolism in patients with nephrotic syndrome.